2-(3-hydroxyphenylamino)benzamide | 1382354-46-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-hydroxyphenylamino)benzamide
• 英文别名: 2-(3-Hydroxyanilino)benzamide
• CAS: 1382354-46-2
• 化学式: C₁₃H₁₂N₂O₂
• 分子量: 228.25
• InChiKey: GOEVZPPFHVSUMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氟溴乙基苯 、 2-(3-hydroxyphenylamino)benzamide 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 以72%的产率得到2-{3-(4-fluorophenethoxy)phenylamino}benzamide
  参考文献：
  名称：

  Design, Synthesis, and Biological Activity of a Novel Series of Human Sirtuin-2-Selective Inhibitors

  摘要：

  Selective inhibitors of human sirtuin 2 (SIRT2), a deacetylase, are candidate therapeutic agents for neurodegenerative diseases such as Parkinson's disease and Huntington's disease as well as potential tools for elucidating the biological functions of SIRT2. On the basis of homology models of SIRT1 and SIRT2, we designed and prepared a series of 2-anilinobenzamide analogues. Enzyme assays using recombinant SIRT1 and SIRT2 revealed that 3'-phenethyloxy-2-anilinobenzamide analogues such as 33a and 33i are potent and selective SIRT2 inhibitors, showing more than 3.5-fold greater SIRT2-inhibitory activity and more than 35-fold greater SIRT2-selectivity compared with AGK2 (3), a previously reported SIRT2-selective inhibitor. Compound 33a also induced a dose-dependent selective increase of alpha-tubulin acetylation in human colon cancer HCT116 cells, indicating selective inhibition of SIRT2 in the cells. These 3'-phenethyloxy-2-anilinobenzamide derivatives represent an entry into a new class of SIRT2-selective inhibitors.

  DOI：

  10.1021/jm3002108
• 作为产物：
  描述：

  3-苄氧基溴苯 在 tris-(dibenzylideneacetone)dipalladium(0) 、 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 乙醇 、 叔丁醇 为溶剂， 反应 6.0h， 生成 2-(3-hydroxyphenylamino)benzamide
  参考文献：
  名称：

  Design, Synthesis, and Biological Activity of a Novel Series of Human Sirtuin-2-Selective Inhibitors

  摘要：

  Selective inhibitors of human sirtuin 2 (SIRT2), a deacetylase, are candidate therapeutic agents for neurodegenerative diseases such as Parkinson's disease and Huntington's disease as well as potential tools for elucidating the biological functions of SIRT2. On the basis of homology models of SIRT1 and SIRT2, we designed and prepared a series of 2-anilinobenzamide analogues. Enzyme assays using recombinant SIRT1 and SIRT2 revealed that 3'-phenethyloxy-2-anilinobenzamide analogues such as 33a and 33i are potent and selective SIRT2 inhibitors, showing more than 3.5-fold greater SIRT2-inhibitory activity and more than 35-fold greater SIRT2-selectivity compared with AGK2 (3), a previously reported SIRT2-selective inhibitor. Compound 33a also induced a dose-dependent selective increase of alpha-tubulin acetylation in human colon cancer HCT116 cells, indicating selective inhibition of SIRT2 in the cells. These 3'-phenethyloxy-2-anilinobenzamide derivatives represent an entry into a new class of SIRT2-selective inhibitors.

  DOI：

  10.1021/jm3002108

文献信息

• Identification of Diketopiperazine-Containing 2-Anilinobenzamides as Potent Sirtuin 2 (SIRT2)-Selective Inhibitors Targeting the “Selectivity Pocket”, Substrate-Binding Site, and NAD⁺-Binding Site
  作者：Paolo Mellini、Yukihiro Itoh、Elghareeb E. Elboray、Hiroki Tsumoto、Ying Li、Miki Suzuki、Yukari Takahashi、Toshifumi Tojo、Takashi Kurohara、Yuka Miyake、Yuri Miura、Yuki Kitao、Masayuki Kotoku、Tetsuya Iida、Takayoshi Suzuki

  DOI：10.1021/acs.jmedchem.9b00255

  日期：2019.6.27

  NAD+-dependent deacetylase SIRT2 represents an attractive target for drug development. Here, we designed and synthesized drug-like SIRT2-selective inhibitors based on an analysis of the putative binding modes of recently reported SIRT2-selective inhibitors and evaluated their SIRT2-inhibitory activity. This led us to develop a more drug-like diketopiperazine structure as a "hydrogen bond (H-bond) hunter"

  NAD +依赖性脱乙酰基酶SIRT2代表了药物开发的诱人靶标。在这里，我们基于对最近报道的SIRT2选择性抑制剂的推定结合模式的分析，设计并合成了药物样SIRT2选择性抑制剂，并评估了其对SIRT2的抑制活性。这导致我们开发了一种更像药物的二酮哌嗪结构，作为“氢键（H键）猎人”，以靶向SIRT2的底物结合位点为目标。预期占据SIRT2的“选择性口袋”的二酮哌嗪和2-苯胺基苯甲酰胺的共轭物硫酰胺53表现出有效的SIRT2选择性抑制作用。SIRT2被53抑制是通过形成53-ADP-核糖缀合物来介导的，这表明53是针对“选择性口袋”的基于机制的抑制剂，底物结合位点和NAD +结合位点。此外，有53个对乳腺癌细胞显示出有效的抗增殖活性，并促进Neuro-2a细胞的神经突向外生长。这些发现应该为癌症和神经系统疾病的新型治疗剂的发现铺平道路。
• Design, Synthesis, and Biological Activity of a Novel Series of Human Sirtuin-2-Selective Inhibitors
  作者：Takayoshi Suzuki、Mohammed Naseer Ahmed Khan、Hideyuki Sawada、Erika Imai、Yukihiro Itoh、Katsura Yamatsuta、Natsuko Tokuda、Jun Takeuchi、Takuya Seko、Hidehiko Nakagawa、Naoki Miyata

  DOI：10.1021/jm3002108

  日期：2012.6.28

  Selective inhibitors of human sirtuin 2 (SIRT2), a deacetylase, are candidate therapeutic agents for neurodegenerative diseases such as Parkinson's disease and Huntington's disease as well as potential tools for elucidating the biological functions of SIRT2. On the basis of homology models of SIRT1 and SIRT2, we designed and prepared a series of 2-anilinobenzamide analogues. Enzyme assays using recombinant SIRT1 and SIRT2 revealed that 3'-phenethyloxy-2-anilinobenzamide analogues such as 33a and 33i are potent and selective SIRT2 inhibitors, showing more than 3.5-fold greater SIRT2-inhibitory activity and more than 35-fold greater SIRT2-selectivity compared with AGK2 (3), a previously reported SIRT2-selective inhibitor. Compound 33a also induced a dose-dependent selective increase of alpha-tubulin acetylation in human colon cancer HCT116 cells, indicating selective inhibition of SIRT2 in the cells. These 3'-phenethyloxy-2-anilinobenzamide derivatives represent an entry into a new class of SIRT2-selective inhibitors.